POD-6.02: A Multicenter, Randomized, Phase III Trial of a Novel, Autologous, Therapeutic Vaccine (Vitespen) vs. Observation as Adjuvant Therapy in Patients at High Risk of Recurrence After Nephrectomy for Renal Cell Carcinoma

✍ Scribed by S. Tanguay; C. Wood; R. Bukowski; P. Champagne; P. Srivastava; B. Escudier; L. Lacombe

• Book ID: 116949712
• Publisher: Elsevier Science
• Year: 2008
• Tongue: English
• Weight: 57 KB
• Volume: 72
• Category: Article
• ISSN: 0090-4295
• DOI: 10.1016/j.urology.2008.08.118